• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: 22nw, Lp bought $1,023,072 worth of shares (1,853,056 units at $0.55)

    8/18/23 4:34:57 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care
    Get the next $SSKN alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    22NW, LP

    (Last) (First) (Middle)
    590 1ST AVE. S
    UNIT C1

    (Street)
    SEATTLE WA 98104

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    STRATA Skin Sciences, Inc. [ SSKN ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    08/16/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock(1) 08/16/2023 P 1,853,056 A $0.5521(2) 5,369,954 I By: 22NW Fund, LP(3)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    22NW, LP

    (Last) (First) (Middle)
    590 1ST AVE. S
    UNIT C1

    (Street)
    SEATTLE WA 98104

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    22NW Fund, LP

    (Last) (First) (Middle)
    590 1ST AVE. S
    UNIT C1

    (Street)
    SEATTLE WA 98104

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    22NW Fund GP, LLC

    (Last) (First) (Middle)
    590 1ST AVE. S
    UNIT C1

    (Street)
    SEATTLE WA 98104

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    22NW GP, Inc.

    (Last) (First) (Middle)
    590 1ST AVE. S
    UNIT C1

    (Street)
    SEATTLE WA 98104

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    English Aron R.

    (Last) (First) (Middle)
    590 1ST AVE. S
    UNIT C1

    (Street)
    SEATTLE WA 98104

    (City) (State) (Zip)
    Explanation of Responses:
    1. This Form 4 is filed jointly by 22NW Fund, LP ("22NW Fund"), 22NW, LP ("22NW"), 22NW Fund GP, LLC ("22NW GP"), 22NW GP, Inc. ("22NW Inc.") and Aron R. English (collectively, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
    2. Represents a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.4799 to $0.5600, inclusive. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
    3. Securities owned directly by 22NW Fund. As the investment manager to 22NW Fund, 22NW may be deemed to beneficially own the securities owned directly by 22NW Fund. As the general partner of 22NW Fund, 22NW GP may be deemed to beneficially own the securities owned directly by 22NW Fund. As the general partner of 22NW, 22NW Inc. may be deemed to beneficially own the securities owned directly by 22NW Fund. Mr. English, as the Portfolio Manager of 22NW, Manager of 22NW GP and President and sole shareholder of 22NW Inc., may be deemed to beneficially own the securities owned directly by 22NW Fund.
    22NW Fund, LP; By: 22NW Fund GP, LLC; By: /s/ Aron R. English, Manager 08/18/2023
    22NW, LP; By: 22NW GP, Inc.; By: /s/ Aron R. English, President and Sole Shareholder 08/18/2023
    22NW Fund GP, LLC; By: /s/ Aron R. English, Manager 08/18/2023
    22NW GP, Inc., By: /s/ Aron R. English, President and Sole Shareholder 08/18/2023
    /s/ Aron R. English 08/18/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SSKN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SSKN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SSKN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rubinstein Samuel sold $18,804 worth of shares (14,094 units at $1.33) and bought $7,028 worth of shares (5,000 units at $1.41), decreasing direct ownership by 51% to 8,766 units (SEC Form 4)

    4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

    11/18/25 4:35:42 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    Director Geiger Uri bought $723,999 worth of shares (230,573 units at $3.14) (SEC Form 4)

    4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

    7/17/24 5:08:57 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    Large owner Accelmed Partners, L.P. bought $723,999 worth of shares (230,573 units at $3.14), increasing direct ownership by 19% to 1,441,835 units (SEC Form 4)

    4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

    7/17/24 5:08:11 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    $SSKN
    SEC Filings

    View All

    SEC Form 10-K filed by Strata Skin Sciences Inc.

    10-K - STRATA Skin Sciences, Inc. (0001051514) (Filer)

    3/25/26 9:33:47 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Strata Skin Sciences Inc.

    EFFECT - STRATA Skin Sciences, Inc. (0001051514) (Filer)

    3/5/26 12:15:03 AM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Strata Skin Sciences Inc.

    EFFECT - STRATA Skin Sciences, Inc. (0001051514) (Filer)

    3/5/26 12:15:07 AM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    $SSKN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    STRATA Skin Sciences Confirms Nasdaq Delisting

    HORSHAM, Pa., Feb. 19, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that a Form 25 has been filed today with the SEC to deregister its common stock under Section 12(b) of the Securities Exchange Act of 1934, as amended ("Exchange Act"), and confirms that trading of the Company's common stock has been suspended from trading on The Nasdaq Capital Market ("Nasdaq") at the opening of business on February 19, 2026. The Company also expects to file a Form 15 with the SEC on or about March

    2/19/26 4:05:00 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    Johns Hopkins Dermatology Expands Advanced Care for Inflammatory and Autoimmune Skin Conditions with Addition of XTRAC® Excimer Laser

    HORSHAM, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative dermatologic treatments, today announces that Johns Hopkins Dermatology has added the XTRAC® 308 nm excimer laser to its clinical treatment offerings. The addition of XTRAC enhances Johns Hopkins' ability to deliver advanced, targeted care for patients living with chronic inflammatory and autoimmune skin diseases, including psoriasis, vitiligo, atopic dermatitis, and other complex dermatologic conditions. The technology will also support ongoing clinical research and academic initiatives within the departm

    2/18/26 8:15:00 AM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    STRATA Skin Sciences Highlights Meta-Analysis Confirming Clinical Efficacy of 308 nm Excimer Laser for Plaque Psoriasis

    HORSHAM, Pa., Feb. 17, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative dermatologic treatments, today highlights findings from a February 2026 systematic review and meta-analysis confirming the clinical efficacy of 308 nm Excimer laser in plaque psoriasis. Published in the Journal of Drugs in Dermatology by investigators from Georgetown University School of Medicine and the Department of Dermatology at MedStar Washington Hospital Center, the analysis evaluated clinical trials assessing the efficacy of the 308 nm excimer laser for plaque psoriasis. Across the included studies,

    2/17/26 8:15:00 AM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    $SSKN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rubinstein Samuel sold $18,804 worth of shares (14,094 units at $1.33) and bought $7,028 worth of shares (5,000 units at $1.41), decreasing direct ownership by 51% to 8,766 units (SEC Form 4)

    4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

    11/18/25 4:35:42 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Operating Officer Gov Shmuel

    4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

    5/15/25 5:21:12 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Accounting Officer Gillings John T

    4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

    5/15/25 5:14:28 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    $SSKN
    Leadership Updates

    Live Leadership Updates

    View All

    Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer

    Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the appointment of Matthew Hill to the position of Chief Financial Officer, effective December 4, 2023. Mr. Hill succeeds Tara Semb, whose departure was announced by the Company on November 9, 2023. "Matt joins our executive leadership team with over 30 years of financial and operational experience, more than 20 years of which has been in the healthcare industry, where he has served as the Chief Financial Officer of four publicly-traded healthcare companies," said Charlie Goodwin, President and

    11/28/23 8:30:00 AM ET
    $APYX
    $PDSB
    $SSKN
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    STRATA Skin Sciences Appoints Dr. Uri Geiger to Chairman of its Board of Directors

    HORSHAM, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the appointment of Dr. Uri Geiger as the Chairman of the Board of Directors. William Humphries will step down as Chairman and continue to serve on the Board, effective July 3, 2023, as he transitions into his role as Chief Executive Officer of Alcami Corporation. "I'm honored to assume the role of Chairman at this pivotal moment in STRATA's growth," said Dr. Uri Geiger, Chairman of STRATA's Board of Directors. "I look forward to levera

    6/30/23 8:00:00 AM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    STRATA Skin Sciences Appoints Patricia S. Walker, M.D., Ph.D. to its Board of Directors

    HORSHAM, Pa., Feb. 14, 2022 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced that effective today, Patricia S. Walker M.D., PhD. has been appointed to its Board of Directors. Dr. Walker's vast experience includes more than 35 years as a practicing dermatologist and as a corporate leader in the medical dermatology, medical aesthetics and pharmaceutical industries, executing clinical research and strategic initiatives for a wide range of companies and educational institutions. "We are delighted to welcome Patty to STRAT

    2/14/22 4:05:00 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    $SSKN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Strata Skin Sciences Inc.

    SC 13G/A - STRATA Skin Sciences, Inc. (0001051514) (Subject)

    11/14/24 2:04:43 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Strata Skin Sciences Inc.

    SC 13D/A - STRATA Skin Sciences, Inc. (0001051514) (Subject)

    7/18/24 7:42:09 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Strata Skin Sciences Inc. (Amendment)

    SC 13G/A - STRATA Skin Sciences, Inc. (0001051514) (Subject)

    2/14/24 4:51:41 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    $SSKN
    Financials

    Live finance-specific insights

    View All

    STRATA Skin Sciences to Report Third Quarter 2025 Financial Results on November 13, 2025 and Provide Corporate Update

    HORSHAM, Penn., Nov. 05, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report third quarter 2025 financial results on Thursday, November 13, 2025 after the market close. STRATA management will subsequently host a conference call at 4:30 p.m. ET on Thursday, November 13, 2025 to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and-answer session. To listen to the conference call, in

    11/5/25 8:00:00 AM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    STRATA Skin Sciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

    HORSHAM, Penn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended June 30, 2025, and provides a corporate update. Second Quarter Highlights Historic expansion of CPT codes for reimbursement for inflammatory and auto-immune skin diseases, effectively tripling the covered patient population in the USPotential acceleration of expanded reimbursement coverage through application for G-codes to gain access by 2026 cycleSubmission of econom

    8/13/25 4:05:00 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    STRATA Skin Sciences to Report Second Quarter 2025 Financial Results on August 13, 2025 and Provide Corporate Update

    HORSHAM, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report second quarter 2025 financial results on Wednesday, August 13, 2025 after the market close. STRATA management will subsequently host a conference call at 4:30 p.m. ET on Wednesday, August 13, 2025 to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and-answer session. To listen to the conference call, i

    7/31/25 8:15:00 AM ET
    $SSKN
    Medical/Dental Instruments
    Health Care